Clinical Trials
31 trialsA Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
Peking University Cancer Hospital & Institute
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Henan Cancer Hospital
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage â…¢A-N2 Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in â…¢b/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Sun Yat-sen University
CHALLENGE
Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
Sichuan Cancer Hospital and Research Institute
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Anhui Medical University
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
China Medical University, China
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
ChineseAMS
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
ChineseAMS
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Beijing Haidian Hospital
RT Plus EGFR-TKI for Wild-type NSCLC
Hangzhou Cancer Hospital
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
First People's Hospital of Hangzhou
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Betta Pharmaceuticals Co., Ltd.
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Betta Pharmaceuticals Co., Ltd.
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
Betta Pharmaceuticals Co., Ltd.
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
Betta Pharmaceuticals Co., Ltd.
Chemotherapy of NSCLC With or Without Icotinib
Nanfang Hospital, Southern Medical University
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
People's Hospital of Guangxi Zhuang Autonomous Region
Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
Zhejiang University
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer
Zhejiang University
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
Betta Pharmaceuticals Co., Ltd.
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Nanfang Hospital, Southern Medical University
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
Shandong Cancer Hospital and Institute
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Zhejiang Cancer Hospital